Tex.
Gov't Code Section 540.0273
Outpatient Pharmacy Benefit Plan
(a)
Subject to Subsection (b), a contract to which this subchapter applies must require the contracting Medicaid managed care organization to develop, implement, and maintain an outpatient pharmacy benefit plan for the organization’s enrolled recipients that:(1)
except as provided by Section 540.0280 (Pharmacy Benefit Plan: Pharmacy Benefits for Child Enrolled in Star Kids Managed Care Program)(2), exclusively employs the vendor drug program formulary and preserves this state’s ability to reduce Medicaid fraud, waste, and abuse;(2)
adheres to the applicable preferred drug list the commission adopts under Subchapter E, Chapter 549 (Provision of Drugs and Drug Information);(3)
except as provided by Section 540.0280 (Pharmacy Benefit Plan: Pharmacy Benefits for Child Enrolled in Star Kids Managed Care Program)(1), includes the prior authorization procedures and requirements prescribed by or implemented under Sections 549.0257 (Prior Authorization Procedures)(a) and (c) and 549.0259 (Applicability of Prior Authorization Requirements to Prior Prescriptions) for the vendor drug program;(4)
does not require a clinical, nonpreferred, or other prior authorization for any antiretroviral drug, as defined by Section 549.0252 (Prior Authorization and Certain Protocol Requirements Prohibited for Certain Antiretroviral Drugs), or a step therapy or other protocol, that could restrict or delay the dispensing of the drug except to minimize fraud, waste, or abuse; and(5)
does not require prior authorization for a nonpreferred antipsychotic drug prescribed to an adult recipient if the requirements of Section 549.0253 (Prior Authorization Prohibited for Certain Nonpreferred Antipsychotic Drugs)(a) are met.(b)
The requirements imposed by Subsections (a)(1)-(3) do not apply, and may not be enforced, on and after August 31, 2023.
Source:
Section 540.0273 — Outpatient Pharmacy Benefit Plan, https://statutes.capitol.texas.gov/Docs/GV/htm/GV.540.htm#540.0273
(accessed Jun. 5, 2024).